XML 97 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Research and development $ 31,033,276 $ 4,403,526
General and administrative 22,531,212 4,439,499
Total operating expenses 53,564,488 8,843,025
Loss from operations (53,564,488) (8,843,025)
Interest expense, net (184,037) (1,206,352)
Merger transaction costs (7,499,353)
Change in fair value of warrants (58,180)
Change in fair value of convertible promissory notes 48,468,678 (50,428,303)
Loss on issuance of commitment shares (890,000)
Net loss (13,727,380) (60,477,680)
Net loss attributable to common stockholders, basic (10,273,695) (60,477,680)
Net loss attributable to common stockholders, diluted $ (10,273,695) $ (60,477,680)
Net loss per share attributable to common stockholders, basic $ (0.07) $ (2.44)
Net loss per share attributable to common stockholders, diluted $ (0.07) $ (2.44)
Weighted-average common stock outstanding, basic 146,672,534 24,752,000
Weighted-average common stock outstanding, diluted 146,672,534 24,752,000